Boniva I.V. Aggressive Pricing Points To Desirability Of Part B Reimbursement

Roche/GlaxoSmithKline's aggressive pricing strategy for Boniva injection relative to the oral formulation indicates the firms feel Medicare Part B is a more advantageous reimbursement environment than Part D